PMID- 11953174
OWN - NLM
STAT- MEDLINE
DCOM- 20031009
LR  - 20121115
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 82
IP  - 4
DP  - 2002 Feb 25
TI  - [Feasibility of using hepatitis B virus surface antigen as target antigen in 
      immunogen therapy against cancer].
PG  - 253-6
AB  - OBJECTIVE: To investigate the feasibility of using hepatitis B virus surface 
      antigen (HbsAg) as a tumor-associated antigen in immunogen therapy against tumor. 
      METHODS: (1) Dendritic cells (DCs) were extracted from bone marrow of mice and 
      cultured. Mature DCs were transfected with adenovirus vector highly expressing 
      HBsAg and enhanced green fluorescence protein (EGFP) (DC-HBsAg). Eight C57BL/6J 
      mice were immunized by intravenous injection of 1 x 10(6) DC-HBsAg. Seven days 
      after, the immunization procedure was boosted by injection of the DC-HBsAg with 
      the same dosage once more. Another eighteen mice were divided into 3 groups, 6 in 
      each, to be injected with DC-EGFP (DCs transfected with 1 x 10(6) adenovector 
      expressing only EGFP), 1 x 10(6) DCs, and PBS of the same volume as controls. One 
      week after the second injection, subcutaneous injection of 7X105 mouse melanoma 
      cells B16 or B16-HBsAg (B16 cells expressing HBsAg) was performed to each mouse. 
      The size of tumor was measured every 2 - 3 days. When the tumor grew to the size 
      of 2cm or caused ulcer the tumor-carrying mice were killed. The mice in the 
      DC-HBsAg group that showed no tumorigenesis 30 days after inoculation of 
      B16-HBsAg were re-inoculated with 7X105 B16-HBsAg. Three normal B6 mice of the 
      same age and sex were used as controls. (2) Other patch of mice were divided into 
      4 groups and injected with DC-HBsAg, DC-EGFP, HBsAg (1 ug/mouse), and PBS in the 
      same way as mentioned above. One week after the second injection at least 5 mice 
      in each group were inoculated with 7X105 B16-HBsAg and 2 mice in each group were 
      killed to have their serum anti-HbsAg titers examined. RESULTS: (1) Seven days 
      after inoculation of B16-HbsAg tumor began to grow in all mice in the three 
      control groups. Tumor was found in 5 of the 8 mice in the DC-HBsA group and the 
      other 3 mice in this group remained free of tumor. However, the size of tumor in 
      these 5 mice was significantly smaller than thate in other groups (P < 0.01). 
      B16-HBsAg was re-inoculated to the three mice that showed no tumor growth 30 days 
      after the first inoculation of B16-HBsAg. However, still no tumor could be found 
      in them. After inoculation of wild type melanoma cell B16 tumorigenesis was seen 
      in the two immunization groups. (2) The titer of anti-HBsAg antibody induced by 
      DC-HBsAg was obviously lower than that induced by recombinant HBsAg vaccine. 
      However, the size of tumor in HBsAg group was obviously smaller than that in 
      recombinant HBsAg group. CONCLUSION: DC-HBsAg induces HBsAg-specific antitumor 
      effect, stronger than that induced by recombinant HBsAg vaccine although the 
      humoral immune response elicited by DC vaccine is much weaker that that induced 
      by recombinant HBsAg vaccine. HBsAg can be used as a target antigen in immunogen 
      therapy for treatment of cancer.
FAU - Qiu, Shuangjian
AU  - Qiu S
AD  - Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      China.
FAU - Ye, Shenglong
AU  - Ye S
FAU - Tang, Zhaoyou
AU  - Tang Z
FAU - Qian, Shiguang
AU  - Qian S
FAU - Li, Lina
AU  - Li L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Hepatitis B Surface Antigens)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*immunology
MH  - *Genetic Therapy
MH  - Hepatitis B Surface Antigens/*genetics
MH  - Immunization
MH  - Male
MH  - Melanoma, Experimental/*therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Transfection
EDAT- 2002/04/16 10:00
MHDA- 2003/10/10 05:00
CRDT- 2002/04/16 10:00
PHST- 2002/04/16 10:00 [pubmed]
PHST- 2003/10/10 05:00 [medline]
PHST- 2002/04/16 10:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2002 Feb 25;82(4):253-6.